Open an account

BioHarvest Sciences

BHST · CANADIAN

$1.72+$0.04 (+2.38%)TodayMarket closed ·
Prev close $1.68

About BHST

BioHarvest Sciences, Inc. develops bio-cell growth platform technology. The firm leverages its patented technology process to grow plant-based molecules, without the need to grow the underlying plant. The company is leveraging its botanical synthesis technology to develop the next generation of science-based and clinically proven therapeutic solutions within two business verticals: as a contract development and production organization on behalf of customers seeking complex molecules, and as a creator of nutraceutical health and wellness products, which include dietary supplements. Its segments include Nutraceuticals and Pharmaceuticals. VINIA is a red grape cell-based supplement, which is a commercial nutraceutical product derived from the Botanical Synthesis platform and is clinically proven to improve blood flow, which enhances physical energy and mental alertness. VINIA contains multiple polyphenols, including Piceid Resveratrol, which is 25x more soluble in water than regular resveratrol.

Employees
89
Headquarters
Vancouver, British Columbia
Listed
Aug 5, 2015
Sector
Consumer Staples
Industry
Personal Care Products
Website
bioharvest.com

BHST key statistics

Market cap
56.14M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
18.81K
Volume
25.35K
Open price
$1.68
High today
$1.83
Low today
$1.65
52 Week high
$12.20
52 Week low
$1.37

BioHarvest Sciences (BHST) at a glance

BioHarvest Sciences (BHST) last traded at $1.72, with a market cap of 56.14M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $1.65 and $1.83. The current price is 4.2% above the day's low and 6.0% below its high.

Volume so far is 25.35K shares, above the average of 18.81K shares a day.

Over the past year BioHarvest Sciences has ranged from $1.37 to $12.20, and now sits 3% of the way up that range.

BioHarvest Sciences met or beat analyst EPS estimates in 1 of the last 4 quarters. In Q1 FY25 it reported -$0.13 per share against an estimate of -$0.1244.

The average analyst price target is $9.30, 440.6% above the current price, from 2 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 2 analyst ratings say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 4 analystsAvg $9.30
Low
$8.50
Now
$1.72
High
$10.31

BHST earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 1 of the last 4 quarters, by 60.4% on average.

  1. Q4 FY24: reported -$0.17 per share against an estimate of -$0.1583
  2. Q2 FY24: reported -$0.055 per share against an estimate of -$0.139
  3. Q3 FY24: reported -$0.10 per share against an estimate of -$0.0695
  4. Q1 FY25: reported -$0.13 per share against an estimate of -$0.1244

BHST news

  • Press releaseNewsfile

    BioHarvest Advances Proprietary Olive Cell Asset to Commercial Readiness, Opening New CDMO Licensing Opportunity

  • Press releaseNewsfile

    Tate & Lyle and Bioharvest Reach Key Milestone in Next-Generation Sweetener Development Programme

  • Press releaseNewsfile

    BioHarvest Sciences Announces Share Repurchase Program

  • Press releaseNewsfile

    BioHarvest Advances Botanical Synthesis Leadership as VINIA Daily Chews Unlock More Value from Its First Consumer Product

  • Press releaseNewsfile

    BioHarvest Sciences to Present at the H.C. Wainwright 28th Annual Global Investment Conference

  • Press releaseNewsfile

    BioHarvest Sciences Registers for Dual Listing on the Tel Aviv Stock Exchange (TASE)

  • Press releaseNewsfile

    BioHarvest Reports Second Quarter 2026 Financial Results and Provides Business Update

  • Press releaseNewsfile

    BioHarvest Secures 20-Ton Manufacturing and Supply Agreement for Rare Botanical Luxury Fragrance

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.